Publicações

Bicalutamide ('Casodex') 150 Mg in Addition to Standard Care in Patients with Nonmetastatic Prostate Cancer: Updated Results from a Randomised Double-Blind Phase Iii Study (Median Follow-Up 5.1 Y) in the Early Prostate Cancer Programme

AuthID
P-000-37F

Author(s)

Wirth, M

Tyrrell, C

Delaere, K

Sanchez Chapado, M

Ramon, J

Wallace, DMA

Hetherington, J

Pina, F

Heyns, C

Borchers, T

Morris, T

Armstrong, J

Group Author(s)

Casodex Early Prostate Canc Trialists

Tipo de Documento

Article

Year published

2005

Publicado

in PROSTATE CANCER AND PROSTATIC DISEASES, ISSN: 1365-7852

Volume: 8, Número: 2, Páginas: 194-200 (7)

Indexing

Wos^®

Scopus^®

Crossref^®

Pubmed^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1038/sj.pcan.4500799

Pubmed: 15931272

SCOPUS: 2-s2.0-23944447196

Wos: WOS:000230755700025

Source Identifiers

ISSN: 1365-7852

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Bicalutamide ('Casodex') 150 Mg in Addition to Standard Care in Patients with Nonmetastatic Prostate Cancer: Updated Results from a Randomised Double-Blind Phase Iii Study (Median Follow-Up 5.1 Y) in the Early Prostate Cancer Programme

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Bicalutamide ('Casodex') 150 Mg in Addition to Standard Care in Patients with Nonmetastatic Prostate Cancer: Updated Results from a Randomised Double-Blind Phase Iii Study (Median Follow-Up 5.1 Y) in the Early Prostate Cancer Programme

Links Úteis

Ajuda